Filament Health Past Earnings Performance
Past criteria checks 0/6
Filament Health's earnings have been declining at an average annual rate of -6%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 107% per year.
Key information
-6.0%
Earnings growth rate
20.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 107.0% |
| Return on equity | -166.5% |
| Net Margin | -192.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Filament Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2 | -4 | 5 | 1 |
| 30 Jun 24 | 2 | -4 | 5 | 1 |
| 31 Mar 24 | 2 | -5 | 5 | 1 |
| 31 Dec 23 | 2 | -5 | 6 | 1 |
| 30 Sep 23 | 1 | -16 | 4 | 1 |
| 30 Jun 23 | 0 | -16 | 4 | 1 |
| 31 Mar 23 | 0 | -16 | 4 | 1 |
| 31 Dec 22 | 0 | -16 | 5 | 1 |
| 30 Sep 22 | 0 | -7 | 5 | 1 |
| 30 Jun 22 | 0 | -7 | 5 | 1 |
| 31 Mar 22 | 0 | -9 | 5 | 1 |
| 31 Dec 21 | 0 | -9 | 6 | 1 |
| 30 Sep 21 | 0 | -7 | 5 | 0 |
Quality Earnings: FH is currently unprofitable.
Growing Profit Margin: FH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FH is unprofitable, and losses have increased over the past 5 years at a rate of 6% per year.
Accelerating Growth: Unable to compare FH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-44%).
Return on Equity
High ROE: FH has a negative Return on Equity (-166.55%), as it is currently unprofitable.